Results 131 to 140 of about 3,073 (170)

Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits

Perfusion, 2021
Introduction: To determine the oxygenator impact on alterations of meropenem (MEM)/vaborbactam (VBR) in a contemporary neonatal/pediatric (1/4-inch) and adolescent/adult (3/8-inch) extra corporeal membrane oxygenation (ECMO) circuit including the Quadrox-i ®
Jeffrey J Cies, Peter Nikolos, Wayne S Moore, Nadji Giliam, Tracy Low, Daniel Marino, Jillian Deacon, Adela Enache, Arun Chopra   +8 more
openaire   +2 more sources

Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection

Expert Opinion on Drug Metabolism & Toxicology, 2018
Meropenem/vaborbactam (M/V) represents the first carbapenem and β-lactamase inhibitor combination approved for treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. Vaborbactam is a novel boronic acid, β-lactamase inhibitor with a high affinity for serine β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC ...
Rodrigo M, Burgos, Mark J, Biagi, Keith A, Rodvold, Larry H, Danziger   +3 more
openaire   +2 more sources

Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

Annals of Pharmacotherapy, 2018
Objective: To review the pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of meropenem/vaborbactam (M/V). Data Sources: A literature search using PubMed and clinicaltrials.gov (June 2013 to December 2017) was conducted using the search terms meropenem ...
Jonathan C, Cho, Monika T, Zmarlicka, Kristy M, Shaeer, Joe, Pardo   +3 more
openaire   +2 more sources

A Brief Review of a New Antibiotic: Meropenem-vaborbactam

The Senior Care Pharmacist, 2019
Meropenem-vaborbactam is a newly approved antibiotic for complex urinary tract infections and to treat carbapenem-resistant Enterobacteriaceae infections. Its advantage over meropenem is the betalactamase inhibitor which slows bacterial resistance. This medication has been studied in numerous countries and has relatively few side effects.
openaire   +2 more sources

Meropenem/vaborbactam

Reactions Weekly, 2021
openaire   +2 more sources

Meropenem / Meropenem-vaborbactam

2017
Meropenem is a broad-spectrum parenteral carbapenem with antimicrobial activity against a wide range of Gramnegative and Gram-positive bacteria, including anaerobes. As a consequence of emerging multidrug resistance, especially in Gram-negative organisms, the clinical reliance on meropenem and other carbapenems increased after their introduction ...
Peleg, A. Y., Harris, P.
openaire   +2 more sources

Resistance to meropenem-vaborbactam in clinical isolates of Enterobacter roggenkampii without previous exposure to vaborbactam

Clinical Microbiology and Infection, 2022
Paula, Navarro-Carrera, Paloma, García-Clemente, Rosa, Gómez-Gil, Rubén, Cáceres-Sánchez, Iván, Bloise, Elias, Dahdouh, Francisco, Moreno-Ramos, Julio, García-Rodríguez, Jesús, Mingorance, Fernando, Lázaro-Perona   +9 more
openaire   +2 more sources

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection

The Journal of Pediatric Pharmacology and Therapeutics
Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract
Ugene, Sano, Rachel, Meyers, Uzma, Hasan, Steven, Smoke   +3 more
openaire   +2 more sources

Meropenem – Vaborbactam

2022
Michelle C. Simpson, Eric G. Schaefer
openaire   +1 more source

Gentamicin/meropenem/vaborbactam

Reactions Weekly, 2021
openaire   +1 more source